Patient Factors in Colorectal Cancer
September 21, 2018
Treatment Planning for Colorectal Cancer
September 21, 2018
Currently Viewing
Mutation Testing for Colorectal Cancer
September 21, 2018
Shared Decision Making in Colorectal Cancer
September 21, 2018
Communication Goals for CRC Patients
September 21, 2018
Varying Levels of Information in the Treatment of Colorectal Cancer
September 21, 2018

Mutation Testing for Colorectal Cancer

Cathy Eng says mutation testing is done to determine which, if any, therapies could be used in addition to chemotherapy.
BY Cathy Eng
PUBLISHED September 17, 2015
Cathy Eng, professor and director, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, says mutation testing is done to determine which, if any, therapies could be used in addition to chemotherapy.

KRAS mutations are very common — occurring in about 30 to 50 percent of patients — and can help a physician steer away from certain expensive drugs.

BRAF mutations are not common and occur in about 5 to 8 percent of patients. A BRAF mutation signifies to a physician that a patient must be treated aggressively upfront.

Unfortunately, Eng says, not all mutations can be targeted with a specific drug.
 

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In